静脈血栓塞栓症(VTE)の疫学的予測

◆英語タイトル:EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2025
◆商品コード:GDHCER122-16
◆発行会社(調査会社):GlobalData
◆発行日:2016年7月18日
◆ページ数:69
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥455,430見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥910,860見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,366,290見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、静脈血栓塞栓症(VTE)の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。
・イントロダクション
・静脈血栓塞栓症(VTE)の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・静脈血栓塞栓症(VTE)の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
【レポートの概要】

EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2025

Summary

Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded flow of blood, which can have serious consequences in the affected individual. VTE can occur at any age, though it is more common in adults ages 60 years and older and is very rare in children. VTE events are highly dangerous and are associated with high rates of mortality and morbidity.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of VTE in the 8MM, from 1,116,358 cases in 2015 to 1,354,846 in 2025, at an Annual Growth Rate (AGR) of 2.14%. The 8MM had 314,886 diagnosed incident cases of Pulmonary Embolism (PE) in 2015 and GlobalData epidemiologists expect the diagnosed incident cases of PE to increase to 377,612 by 2025, at an AGR of 1.99%. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of Deep Vein Thrombosis (DVT) in the 8MM to increase from 801,472 cases in 2015 to 977,234 cases by 2025, at an AGR of 2.19%. GlobalData epidemiologists also forecast the number of medically ill patients at risk for VTE to increase in the 8MM from 44,611,144 in 2015 to 54,143,874 in 2025. In addition, GlobalData epidemiologists forecast the number of total knee replacement and revision procedures to grow from 1,532,360 in 2015 to 1,867,289 in 2025. Furthermore, the number of hip replacements is forecast to grow 1,220,965 in 2015 to 1,512,215 in 2025. GlobalData epidemiologists have identified the predominant drivers of this market to be changes in country-specific incidence and procedure rates, as well as in the underlying demographic trends.

Scope

- The Venous thromboembolism (VTE) EpiCast Report is an overview of the risk factors, comorbidities, and the global and historical trends for VTE in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of PE, DVT, and VTE; the number of VTE attacks; the number of medically ill discharges that are at risk for VTE; the number of primary total knee replacements and revisions; and the number of hip replacements, each segmented by sex and age. Additionally, it includes a forecast for the number of recurrent VTE cases at one and 10 years after incident event, and the number of diagnosed VTE cases with cancer as comorbidity.
- The VTE epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The VTE EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global VTE market.
- Quantify patient populations in the global VTE market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for VTE therapeutics in each of the markets covered.

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Epidemiology 7
2.1 Disease Background 7
2.2 Risk Factors and Comorbidities 8
2.3 Global Trends 10
2.4 Forecast Methodology 11
2.4.1 Sources Used 11
2.4.2 Forecast Assumptions and Methods 17
2.4.3 Sources Not Used 33
2.5 Epidemiological Forecast for VTE (2015-2025) 34
2.5.1 Pulmonary Embolism 34
2.5.2 Deep Vein Thrombosis 37
2.5.3 VTE 40
2.5.4 Number of Hospital Discharges Meeting Criteria for Medically Ill and Those at Risk for VTE 50
2.5.5 Number of Primary Total Knee Replacements and Revisions 51
2.5.6 Number of Hip Replacements 53
2.6 Discussion 55
2.6.1 Epidemiological Forecast Insight 55
2.6.2 Limitations of the Analysis 56
2.6.3 Strengths of the Analysis 57
3 Appendix 58
3.1 Bibliography 58
3.2 Physicians and Specialists Included in this Study 61
3.3 About the Authors 64
3.3.1 Epidemiologists 64
3.3.2 Reviewers 64
3.3.3 Global Director of Therapy Analysis and Epidemiology 65
3.3.4 Global Head of Healthcare 66
3.4 About GlobalData 67
3.5 About EpiCast 67
3.6 Disclaimer 68

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for VTE 9
Table 2: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of PE 12
Table 3: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of DVT 13
Table 4: 8MM, Sources Used to Forecast the Number of Hospital Discharges that Meet the Criteria for Medically Ill 14
Table 5: 6MM, Sources Used to Forecast Primary Total Knee Replacements 15
Table 6: 6MM, Sources Used to Forecast the Rate of Primary Total Knee Replacement Requiring Revisions 15
Table 7: Japan and China, Sources Used to Forecast Primary Total Knee Replacements and Revisions 16
Table 8: 8MM, Sources Used to Forecast Hip Replacements 16
Table 9: 8MM, Diagnosed Incident Cases of PE, All Ages, Both Sexes, Select Years 2015-2025 35
Table 10: 8MM, Diagnosed Incident Cases of DVT, All Ages, Both Sexes, Select Years 2015-2025 38
Table 11: 8MM, Diagnosed Incident Cases of VTE, All Ages, Both Sexes, Select Years 2015-2025 41
Table 12: 8MM, Age-Specific Diagnosed Incident Cases of VTE, Both Sexes, N (Row %), 2015 43
Table 13: 8MM, Sex-Specific Diagnosed Incident Cases of VTE, Both Sexes, N (Row %), 2015 45
Table 14: 8MM, Number of Recurrent VTE Cases One and 10 Years After Incident VTE Event, Both Sexes, All Ages, N, 2015 47
Table 15: 8MM, Number of VTE Cases With Cancer Comorbidity, Both Sexes, All Ages, N, 2015 and 2025 48
Table 16: 8MM, Number of VTE Attacks, Both Sexes, All Ages, N, 2015-2025 49
Table 17: 8MM, Number of Hospital Discharges Meeting Criteria for Medically Ill; Those at risk for VTE, Both Sexes, Ages ≥40 Years, N, 2015 51
Table 18: 8MM, Number of Primary Total Knee Replacements and Revisions, Both Sexes, Ages ≥15 Years 52
Table 19: 8MM, Number of Hip Replacements, Both Sexes, Ages ≥15 Years 54

1.2 List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of PE, All Ages, Both Sexes, Select Years 2015-2025 36
Figure 2: Age-Standardized Diagnosed Incidence of PE, All Ages, Cases Per 100,000, 2015 37
Figure 3: 8MM, Diagnosed Incident Cases of DVT, All Ages, Both Sexes, Select Years 2015-2025 39
Figure 4: Age-Standardized Diagnosed Incidence of DVT, All Ages, Cases Per 100,000 Population, 2015 40
Figure 5: 8MM, Diagnosed Incident Cases of VTE, All Ages, Both Sexes, Select Years 2015-2025 42
Figure 6: 8MM, Age-Specific Diagnosed Incident Cases of VTE, Both Sexes, N (Row %), 2015 44
Figure 7: 8MM, Sex-Specific Diagnosed Incident Cases of VTE, Both Sexes, N, 2015 46
Figure 8: 8MM, Number of VTE Attacks, Both Sexes, All Ages, N, 2015-2025 50
Figure 9: 8MM, Number of Primary Total Knee Replacements and Revisions, Both Sexes, Ages ≥15 Years 53
Figure 10: 8MM, Number Hip Replacements, Both Sexes, Ages ≥15 Years 55

【レポートのキーワード】

静脈血栓塞栓症(VTE)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[静脈血栓塞栓症(VTE)の疫学的予測]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月05日現在 219,162 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆